About genprex inc - GNPX
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.
GNPX At a Glance
Genprex, Inc.
3300 Bee Cave Road
Austin, Texas 78746
| Phone | 1-877-774-4679 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -16,228,953.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GNPX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.723 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.40 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
GNPX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,248,381.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GNPX Liquidity
| Current Ratio | 3.843 |
| Quick Ratio | 3.843 |
| Cash Ratio | 3.601 |
GNPX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -227.243 |
| Return on Equity | -338.737 |
| Return on Total Capital | -203.833 |
| Return on Invested Capital | -338.737 |
GNPX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |